On the contrary, claudin-low/ER-negative/HER2-negative cancers had a lower prevalence of TP53 mutations than basal ER-negative/HER2-negative cancers, which showed TP53 mutations in 86.9% of cases (Fisher’s exact test p = 0.0001, Table 4). Here, ERBB2 is linked to cancer.